Ligand Pharmaceuticals (NASDAQ:LGND) Issues FY 2025 Earnings Guidance

Ligand Pharmaceuticals (NASDAQ:LGND) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.000-6.250 for the period, compared to the consensus estimate of 6.140. The company issued revenue guidance of $180.0 million-$200.0 million, compared to the consensus revenue estimate of $188.8 million.

Analysts Set New Price Targets

LGND has been the topic of a number of analyst reports. Oppenheimer increased their price objective on shares of Ligand Pharmaceuticals from $135.00 to $147.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. HC Wainwright reissued a “buy” rating on shares of Ligand Pharmaceuticals in a research note on Wednesday, December 11th. Benchmark reaffirmed a “buy” rating and issued a $135.00 target price on shares of Ligand Pharmaceuticals in a report on Monday, December 23rd. Royal Bank of Canada boosted their price target on Ligand Pharmaceuticals from $141.00 to $143.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Finally, Barclays upped their price objective on Ligand Pharmaceuticals from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $147.00.

Ligand Pharmaceuticals Price Performance

Ligand Pharmaceuticals stock opened at $114.80 on Thursday. The business has a 50 day moving average of $113.99 and a 200-day moving average of $110.97. The company has a market capitalization of $2.17 billion, a P/E ratio of 45.74 and a beta of 1.04. Ligand Pharmaceuticals has a 1 year low of $67.72 and a 1 year high of $129.90.

Ligand Pharmaceuticals (NASDAQ:LGND) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($1.64) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.37 by ($3.01). Ligand Pharmaceuticals had a net margin of 29.68% and a return on equity of 4.95%. Equities analysts anticipate that Ligand Pharmaceuticals will post 1.73 EPS for the current year.

Insiders Place Their Bets

In other Ligand Pharmaceuticals news, CFO Octavio Espinoza sold 2,104 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $116.37, for a total transaction of $244,842.48. Following the completion of the transaction, the chief financial officer now owns 20,647 shares in the company, valued at approximately $2,402,691.39. This trade represents a 9.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 5.90% of the company’s stock.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.